Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I am Dr. Siddharth Munot, MD, dermatologist (DVL), having completed my MBBS from JJ Hospital, Mumbai, and my postgraduate training from KLE Hospital, Karnataka. I am also a member of the Indian Association of Dermatologists, Venereologists, and Leprologists (IADVL). I am also the co-founder of Clinderma, which aims to bridge the gap between clinical dermatology and accessible, patient-centric skincare solutions for acne, pigmentation, and scars. Over the years, my clinical focus has been on evidence-based dermatology, with particular expertise in acne management using root-cause–targeted approaches, as well as pigmentation and scar management.

Q2. As more consumers move from cosmetic products to clinically driven solutions, how is this changing expectations around efficacy, timelines, and outcomes?

There is definitely a noticeable shift toward clinically driven skincare, and with that, patient expectations have become more outcome-oriented. People now expect visible and measurable results rather than just temporary improvement. However, there is still a gap in understanding timelines—clinical treatments work, but they require consistency and patience. As dermatologists, we are increasingly spending time educating patients that true skin improvement, especially in conditions like acne or pigmentation, typically takes weeks to months, not days. The focus is gradually shifting from quick fixes to sustainable results, which is a positive change.

Q3. With skincare advice widely available online, how do you see the gap between social media trends and clinically appropriate treatment evolving?

The gap is quite significant and, in many cases, widening. Social media often oversimplifies complex skin conditions and promotes a one-size-fits-all approach. In contrast, dermatology is highly individualized—what works for one patient may not work for another. We are seeing patients come in with over-layered routines or inappropriate combinations of actives inspired by trends. Going forward, I think the role of dermatologists will be not just to treat but also to actively counter misinformation and guide patients toward personalized, evidence-based care.

Q4. Are you seeing a rise in patients with compromised skin barriers due to overuse of actives, and how is that shaping treatment approaches?

Yes, very clearly. Barrier damage has become one of the most common presentations in recent years, largely due to overuse or misuse of active ingredients such as retinoids, exfoliating acids, and multiple serums. This has significantly shifted our treatment approach. Instead of starting aggressive treatments, we often begin with barrier repair—simplifying routines, focusing on gentle skincare, and gradually reintroducing actives. It’s a reminder that more is not always better when it comes to skincare.

Q5. Are consumers moving toward preventive skincare, or does the market still remain largely driven by reactive treatment of visible issues?

While there is growing awareness about preventive skincare, especially among younger consumers, the market is still largely driven by reactive treatment. Most patients seek help only after visible concerns like acne, pigmentation, or aging signs appear. That said, there is a gradual shift, particularly in urban populations, toward maintenance and prevention—such as early sunscreen use, antioxidant-based routines, and early intervention. This trend is likely to grow further as education improves.

Q6. With easy access to products, how significant is the issue of self-diagnosis and incorrect treatment, and what impact does it have clinically?

Self-diagnosis has become extremely common, and it often leads to incorrect or delayed treatment. Patients frequently misidentify their condition—acne versus rosacea, fungal infections versus acne, or pigmentation types—and start inappropriate treatments. Clinically, this can worsen the condition, prolong recovery, and sometimes lead to complications like scarring or persistent pigmentation. It also makes treatment more challenging, as we often have to first undo the damage before initiating the correct therapy.

Q7. If you were an investor looking at companies within the space, what critical question would you pose to their senior management?

The key question I would ask is: “Is your approach truly evidence-based and patient-centric, or is it primarily trend-driven?”

In dermatology, long-term credibility depends on scientific backing, safety, and consistency of results. I would like to understand whether the company prioritizes clinical validation, dermatological input, and sustainable outcomes over short-term marketing gains. In a rapidly expanding market, the differentiator will ultimately be trust and clinical efficacy, not just visibility.